

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number  
**WO 2004/043480 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 38/00**
- (21) International Application Number:  
PCT/US2003/028315
- (22) International Filing Date:  
10 September 2003 (10.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/289,772 7 November 2002 (07.11.2002) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant and  
(72) Inventor: PEYMAN, Gholam, A. [US/US]; 8654 Pontchartrain Blv., Unit #1, New Orleans, LA 70124 (US).
- (74) Agents: JOSEPHIC, David, J. et al.; Wood, Herron & Evans, L.L.P., 2700 Carew Tower, Cincinnati, OH 45202 (US).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/043480 A2

(54) Title: TREATMENT OF OCULAR DISEASE

(57) Abstract: A method and article to treat ocular disease with Cyclosporin A alone or with compounds related to Cyclosporin A for intraocular injection or implantation. Treatment does not result in ocular toxicity and encompasses age related macular degeneration, retinitis pigmentosa, and retinopathy such as diabetic retinopathy.

## TREATMENT OF OCULAR DISEASE

### Field of the Invention

The invention is directed to therapeutic treatment of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy with Cyclosporin A.

### 5 Background

The immunomodulator Cyclosporin A (cyclosporine, topical formulation Arrestase®, Allergan Inc.) has been used to treat glaucoma, corticosteroid-induced ocular hypertension, allograft rejection, infections, and ocular surface disease. Its use has been reported for the treatment of uveitis (inflammation of the uvea) by topical,  
10 intravitreal or systemic administration with doses of 0.05%, 0.1%, and 0.5%. Cyclosporin A has good penetration into the cornea but not into the anterior chamber, and does not increase intraocular pressure or cause cataracts. Its known toxicity had previously limited its use for other ocular diseases.

### Summary of the Invention

15 A method of treating age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy in the absence of substantial toxicity by administering Cyclosporin A in an effective amount and in a pharmaceutically acceptable formulation. "Treating" includes preventing progression of pre-existing

disease, delaying onset and/or severity of disease, and ameliorating or reducing the severity, frequency, duration, etc., of one or more symptoms of disease.

In one embodiment, Cyclosporin A is injected intraocularly, for example by subconjunctival, intravitreal, subretinal, or retrobulbar injection. For subconjunctival  
5 injection, a concentration in the range of about 1 ng/ml to about 500 µg/ml may be used. For intravitreal injection, a concentration in the range of about 1 µg/0.1 ml to about 1000 µg/0.1 ml may be used; one concentration that may be used is about 50 µg/0.1 ml. For subretinal injection, a concentration in the range of about 1 µg/0.1 ml to about 100 µg/0.1 ml may be used. For retrobulbar injection, a concentration in  
10 the range of about 20 µg/ml to about 1000 µg/ml may be used. Cyclosporin A may be administered in an aqueous-based solution, for example, bound to liposomes, or it may be dissolved in an organic solvent. In another alternative embodiment, Cyclosporin A may also be provided in an inert physiologically acceptable carrier such as a microsphere, liposome, capsule or polymeric matrix by injection or by  
15 surgical implantation in the eye or on the eye. Aqueous solvents that may be used include, but are not limited to, 0.9% saline and 5% dextrose. Organic solvents that may be used include, but are not limited to, dimethylsulfoxide (DMSO) or an alcohol. An implant may provide a time-release form of Cyclosporin A to achieve a constant dose of drug.

20 A method is also disclosed to reduce the onset or progression of diabetic retinopathy, age-related macular degeneration and/or retinitis pigmentosa, by intraocularly administering a composition containing Cyclosporin A, either alone or with other compounds that are related to Cyclosporin A, as the active agent in a pharmaceutically acceptable formulation and in an effective amount without causing  
25 substantial toxicity. The composition may contain Cyclosporin A as the sole active

agent, the other agents being those that do not materially affect the basic properties of Cyclosporin A. Alternatively, the composition may contain other active agents, such as tacrolimus, besides Cyclosporin A. The composition may be injected or implanted in the eye.

5                   The invention encompasses a method to treat a patient by intraocularly administering a composition containing Cyclosporin A as the active agent in a pharmaceutically acceptable formulation and in an amount effective to treat macular degeneration, retinopathy, or retinitis pigmentosa without substantial ocular toxicity. The composition is injected or implanted in the eye, and may be administered in a  
10   time-release formulation.

                  A sustained release formulation, such as a matrix, may be loaded with an amount of Cyclosporin A that would be toxic if released at a non-controlled rate, or a supratherapeutic amount, but which is formulated to release a non-toxic therapeutic amount of Cyclosporin A over a period of time. For example, a matrix  
15   may contain at least about 1 mg Cyclosporin A and may sustainably release a non-toxic maintenance dose of Cyclosporin A. Such a matrix may be a diffusible walled reservoir and may be lipid, polyvinyl alcohol, polyvinyl acetate, polycaprolactone, poly(glycolic) acid, and/or poly(lactic)acid.

                  The invention will further be appreciated with respect to the following  
20   detailed description.

#### **Detailed Description**

Cyclosporin A is a cyclic peptide produced by *Trichoderma polysporum*. It is available commercially, for example, from Sigma Chemicals (St. Louis, MO). It is an immunosuppressant and acts in a particular subset of T

lymphocytes, the helper T cells. Cyclosporin A exerts an immunosuppressant effect by inhibiting production of the cytokine interleukin 2. Each of Cyclosporin A and tacrolimus, another immunosuppressant, produce significant renal and hepatic toxicity when each is administered systemically; because of this toxicity, they are not  
5 administered together.

Direct intraocular injection of 200 µg Cyclosporin A or less is non-toxic. Ocular toxicity may manifest as a gross and/or histologic retinal and/or vitreous toxic reaction. Evidence of such a toxic reaction may include one or more of white vitreous bodies, white vitreous opacities, electroretinography abnormalities such as reduction  
10 in mean B-wave amplitude in both scotopic and photopic conditions, occlusion of the temporal retinal vessels, and fibrin deposits.

Cyclosporin A may be injected intraocularly using intravitreal (into the vitreous), subconjunctival (into the subconjunctival), subretinal (under the retina), or retrobulbar (behind the eyeball) injection. For subconjunctival injection, a Cyclosporin  
15 A dose in the range of about 1 ng/ml to about 500 µg/ml may be used. For intravitreal injection, a Cyclosporin A dose in the range of about 1 µg/0.1 ml to about 1000 µg/0.1 ml may be used. For retrobulbar injection, a Cyclosporin A dose in the range of about 20 µg/ml to about 1000 µg/ml may be used. For subretinal injection, a Cyclosporin A dose in the range of about 1 µg/0.1 ml to about 100 µg/0.1 ml may  
20 be used.

Cyclosporin A may be administered intraocularly in a composition in which it is the only active agent. Alternatively, Cyclosporin A may be administered intraocularly in a composition with related compounds. Related compounds are other immunosuppressants that include, but are not limited to, tacrolimus,  
25 cyclophosphamide, sirolimus, atropine, thiopepa, methotrexate, azathioprine

(imuran), interferons, infliximab, etanercept, mycophenolate mofetil, 15-deoxyspergualin, thalidomide, glatiramer, leflunomide, vincristine, cytarabine, etc.

In one embodiment, the composition containing Cyclosporin A is administered in an amount or at a dose that does not result in substantial toxicity to the eye. As used herein, a lack of substantial toxicity encompasses both the absence of any manifestations of toxicity, as well as manifestations of toxicity which one skilled in the art would consider not sufficiently detrimental to decrease or cease treatment. As one example, fibrin deposits may be present indicating some toxicity, but less than substantial toxicity if their duration, number, etc., does not warrant that treatment be curtailed or stopped. As another example, white vitreous bodies and fibrin bodies may be present indicating some toxicity, but less than substantial toxicity if their duration, number, etc., does not warrant that treatment be curtailed or stopped.

Direct intraocular injection of a dose up to about 200 µg Cyclosporin A occurs without substantial toxicity to the patient. The intravenous solution form of Cyclosporin A may be diluted to achieve the indicated concentration using 0.9% NaCl or 5% dextrose, or an organic solvent such as dimethylsulfoxide (DMSO) or alcohol. Intraocular administration may be by any of the routes and formulations previously described. For injection, either a solution, emulsion, suspension, capsular formulation of microspheres or liposomes, etc. may be used.

Cyclosporin A may be administered surgically as an ocular implant. As one example, a reservoir container having a diffusible wall of polyvinyl alcohol or polyvinyl acetate and containing milligram quantities of Cyclosporin A may be implanted in or on the sclera. As another example, Cyclosporin A in milligram quantities may be incorporated into a polymeric matrix having dimensions of about 2 mm by 4 mm, and made of a polymer such as polycaprolactone, poly(glycolic acid,

poly(lactic) acid, or a polyanhydride, or a lipid such as sebacic acid, and may be implanted on the sclera or in the eye. This is usually accomplished with the patient receiving either a topical or local anesthetic and using a small (3-4 mm incision) made behind the cornea. The matrix, containing Cyclosporin A, is then inserted  
5 through the incision and sutured to the sclera using 9-0 nylon.

Cyclosporin A may be contained within an inert matrix for injection into the eye. As one example of an inert matrix, liposomes may be prepared from dipalmitoyl phosphatidylcholine (DPPC), such as egg phosphatidylcholine (PC), a lipid having a low heat transition. Liposomes are made using standard procedures  
10 as known to one skilled in the art. Cyclosporin A, in amounts ranging from nanogram to microgram to milligram quantities, is added to a solution of egg PC, and the lipophilic drug binds to the liposome.

A time-release drug delivery system may be implanted intraocularly to result in sustained release of the active agent over a period of time. The implantable  
15 structure may be in the form of a capsule of any of the polymers previously disclosed (e.g., polycaprolactone, poly(glycolic) acid, poly(lactic) acid, polyanhydride) or lipids that may be formulated as microspheres. As an illustrative example, Cyclosporin A may be mixed with polyvinyl alcohol (PVA), the mixture then dried and coated with ethylene vinyl acetate, then cooled again with PVA. In a formulation for intraocular  
20 injection, the liposome capsule degrades due to cellular digestion and can be a slow release drug delivery system, allowing the patient a constant exposure to the drug over time.

In a time-release formulation, the microsphere, capsule, liposome, etc. may contain a concentration of Cyclosporin A that could be toxic if it were  
25 administered as a bolus dose. The time-release administration, however, is

formulated so that the concentration released over any period of time does not exceed a toxic amount. This is accomplished, for example, through various formulations of the vehicle (coated or uncoated microsphere, coated or uncoated capsule, lipid or polymer components, unilamellar or multilamellar structure, and combinations of the above, etc.). Other variables may include the patient's pharmacokinetic-pharmacodynamic parameters (e.g., body mass, gender, plasma clearance rate, hepatic function, etc.).

Depending upon the amount of Cyclosporin A provided in the formulation, a patient could be dosed over a period of years from a single implant or injection. As illustrative but non-limiting examples, a capsule can be loaded with 1-2 mg of Cyclosporin A; if the capsule is formulated to release a few micrograms of drug per day, the patient could be dosed for about 1000 days, or almost three years. As another example, if the capsule is loaded with 5 mg of drug, the patient could be dosed for about fifteen years. Such a formulation provides benefits which include accurate dosing with heightened patient convenience, because intervention is required in some cases only once or twice a decade or even less frequently.

The formation and loading of microspheres, microcapsules, liposomes, etc. and their ocular implantation are standard techniques known by one skilled in the art, for example, the use a ganciclovir sustained-release implant to treat cytomegalovirus retinitis, disclosed in Vitreoretinal Surgical Techniques, Peyman et al., Eds. (Martin Dunitz, London 2001, chapter 45); Handbook of Pharmaceutical Controlled Release Technology, Wise, Ed. (Marcel Dekker, New York 2000), the relevant sections of which are incorporated by reference herein in their entirety.

Cyclosporin A, either alone or in combination with other agents, may be administered intraocularly and without substantial toxicity, to treat retinopathy such



as occurs in diabetic patients, macular degeneration, and retinitis pigmentosa, using the methods and formulations previously described. As described, this may be achieved by one or a combination of factors, such as by slowing disease progression, lessening its severity, lengthening the time of onset, etc.

5               Diabetic retinopathy is a leading cause of blindness. Patients with diabetes mellitus have an absolute or relative lack of circulating insulin and, through a variety of factors, frequently present with vascular changes in the retina. These changes manifest in retinal microaneurysms, small hemorrhages, and exudates, and lead to the formation of scar tissue. New blood vessels may form around the optic  
10     disk (proliferative retinopathy). Over time, the cumulative results of such vascular effects lead to ocular pathologies which, ultimately, decrease vision in the diabetic patient. Thus, compositions and methods which reduce these vascular changes, or reduce their effects, improve the chances of a diabetic patient either maintaining vision, or at least slowing loss of vision.

15               Macular degeneration, also called age-related macular degeneration is a pathological condition that results in proliferation of new blood vessels in the subretinal area. While the presence of the new vessels themselves is not problematic, the new vessels leak blood and other serous fluid which accumulate in surrounding spaces. It is this fluid accumulation that leads to visual impairment. For  
20     example, in the retina, both the large vessels and the capillaries normally have intact vessel walls. In the choroid, the large vessels normally have intact vessel walls, but the capillary walls or membranes contain fenestrations or openings. Any endogenous or exogenous fluid present in these capillaries, for example, blood, serous fluid, solubilized drug, etc. will leak outside the vessels and into the surrounding area. The  
25     accumulation of fluid can result in serous and hemorrhagic detachment of the retinal

pigment epithelium and neurosensory retina, and can lead to loss of vision due to fibrous deform scarring. Patients with an early stage of age-related macular degeneration can be diagnosed by the presence in the eye of abnormal clumps of pigments, termed drusen, which are dead outer segments of photoreceptor cells under the retinal pigment epithelium. The presence of large, soft drusen in the eye indicates a pre-stage of exudative age-related macular degeneration, and places these patients at higher-than-average risk for developing neovascularizations, especially if one eye is already affected.

Retinitis pigmentosa is a general term that encompasses a disparate group of disorders of rods and cones, which are the sensory structures in the retina. While retinitis pigmentosa is a genetic disorder, and is not an inflammatory process, one manifestation of the disease is the presence of irregular black deposits of clumped pigment in the peripheral retina. Thus, there is likely at least some immune component to retinitis pigmentosa.

While not being bound by a specific theory or mechanism, it is possible that the therapeutic efficacy of Cyclosporin A may involve its immunosuppressant activity. For example, diabetic patients treated with immunosuppressant drugs for reasons unrelated to vision develop less retinopathy over time than other diabetic patients. As another example, the drusen that is present in age-related macular degeneration constitutes a chronic inflammatory stimulus that becomes the target for encapsulation by a variety of inflammatory mediators, such as compliment. Treatment with immunosuppressant drugs may ameliorate this reaction. Immunosuppressant therapy results in decreased numbers of circulating immunocompetent cells such as lymphocytes. These cells otherwise have the potential to participate in an immune response, to lodge within the small capillaries

and arterioles of the eye to form blockages and hence occlude blood flow, etc. In addition to lymphocytes, other hematopoietic cells may also be affected by immunotherapy, and include erythrocytes (red blood cells), megakaryocytes (precursors to platelets) and thrombocytes (platelets), and other leukocytes (white  
5 blood cells), such as monocytes and granulocytes. Local or *in situ* administration of immunosuppressant agents to the eye decreases the number of these cells. This results in reduction in the immune response, less blockage, increased blood flow, and increased patency of the ocular vessels.

Cyclosporin A in any of the previously described formulations, dosages,  
10 compositions, routes of administration, etc. may be employed. Because Cyclosporin A is injected or implanted directly in the eye, the undesirable effects brought about by administration of systemic therapy with Cyclosporin A (e.g., decreased peripheral blood leukocyte count, susceptibility to infections, hepatic and renal toxicity of the immunosuppressant agent itself, etc.) are absent. Cyclosporin A  
15 and related compounds may be administered by intraocular injection and/or intraocular implantation of a loaded capsule, microsphere, etc. (collectively termed an implant) to treat retinopathy, macular degeneration, and/or retinitis pigmentosa. The implant may release Cyclosporin A over a period of time, as previously described, so that high doses of drug can be loaded into the implant, but the patient  
20 will receive a low dose sustained concentration. That is, the matrix may be loaded or formulated so that it contains what would otherwise be a toxic or supratherapeutic amount of Cyclosporin A if the drug was released in a non-controlled manner.

It should be understood that the embodiments of the invention shown and described in the specification are only preferred embodiments of the inventor  
25 who is skilled in the art and are not limiting in any way. Therefore, various changes,

modifications or alterations to these embodiments may be made or resorted to without departing from the spirit of the invention and the scope of the following claims.

What is claimed is:

1. A method to treat a patient comprising intraocularly administering to the patient a composition consisting essentially of Cyclosporin A in a pharmaceutically acceptable formulation and amount effective to treat macular degeneration, retinopathy, or retinitis pigmentosa without substantial toxicity to the patient.
2. The method of claim 1 comprising administering by intraocular injection or intraocular implantation.
3. The method of claim 1 comprising administering by retrobulbar, intravitreal, intraretinal, or subconjunctival injection.
4. The method of claim 1 comprising administering by implanting a matrix comprising Cyclosporin A.
5. The method of claim 4 providing sustained release of Cyclosporin A.
6. The method of claim 4 wherein the matrix is sutured to the sclera.
7. The method of claim 4 wherein the matrix contains at least about 1 mg Cyclosporin A and sustainedly releases a non-toxic maintenance dose of Cyclosporin A.

8. The method of claim 2 wherein injection is subconjunctival at a dose in the range of about 1 ng/ml to about 500  $\mu$ g/ml, intravitreal at a dose in the range of about 1  $\mu$ g/0.1 ml to about 1000  $\mu$ g/0.1 ml, retrobulbar at a dose in the range of about 20  $\mu$ g/ml to about 1000  $\mu$ g/ml, or subretinal at a dose in the range of about 1  $\mu$ g/0.1 ml to about 100  $\mu$ g/0.1 ml.
9. The method of claim 2 wherein Cyclosporin A is injected at a dose in the range of about 20  $\mu$ g/ml to about 1000  $\mu$ g/ml.
10. The method of claim 1 for treating diabetic retinopathy.

11. A method to treat a patient comprising intraocularly administering to the patient a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and amount effective to treat macular degeneration, retinopathy, or retinitis pigmentosa without substantial toxicity to the patient.
12. The method of claim 11 comprising administering by intraocular injection or intraocular implantation.
13. The method of claim 11 comprising administering by retrobulbar, intravitreal, intraretinal, or subconjunctival injection.
14. The method of claim 11 comprising administering by implanting a matrix comprising Cyclosporin A.
15. The method of claim 14 providing sustained release of Cyclosporin A.
16. The method of claim 14 wherein the matrix is sutured to the sclera.
17. The method of claim 14 wherein the matrix contains at least about 1 mg Cyclosporin A and sustainedly releases a non-toxic maintenance dose of Cyclosporin A.

18. The method of claim 12 wherein injection is subconjunctival at a dose in the range of about 1 ng/ml to about 500 µg/ml, intravitreal at a dose in the range of about 1 µg/0.1 ml to about 1000 µg/0.1 ml, retrobulbar at a dose in the range of about 20 µg/ml to about 1000 µg/ml, or subretinal at a dose in the range of about 1  
5 µg/0.1 ml to about 100 µg/0.1 ml.

19. The method of claim 12 wherein Cyclosporin A is injected at a dose in the range of about 20 µg/ml to about 1000 µg/ml.

20. The method of claim 11 for treating diabetic retinopathy.

21. The method of claim 11 wherein the composition further comprises an immunosuppressant selected from the group consisting of tacrolimus, cyclophosphamide, sirolimus, atropine, thiopepa, methotrexate, azathioprine, interferons, infliximab, etanercept, mycophenolate mofetil, 15-deoxyspergualin,  
5 thalidomide, glatiramer, leflunomide, vincristine, cytarabine, and combinations thereof.



22. An article of manufacture comprising a physiologically acceptable implantable matrix comprising a supratherapeutic amount of Cyclosporin A.
23. The article of claim 22 wherein Cyclosporin A is in or on the matrix.
24. The article of claim 22 wherein the matrix is a diffusible walled reservoir.
25. The article of claim 22 wherein the matrix comprises a substance selected from the group consisting of lipid, polyvinyl alcohol, polyvinyl acetate, polycaprolactone, poly(glycolic)acid, poly(lactic)acid, and combinations thereof.
26. The article of claim 22 wherein the matrix contains at least about 1 mg Cyclosporin A.
27. The article of claim 22 wherein the matrix contains Cyclosporin A in an amount ranging from about 1 mg Cyclosporin A to about 10 mg Cyclosporin A.
28. The article of claim 22 wherein the matrix further comprises an immunosuppressant selected from the group consisting of tacrolimus, cyclophosphamide, sirolimus, atropine, thiopepa, methotrexate, azathioprine, interferons, infliximab, etanercept, mycophenolate mofetil, 15-deoxyspergualin, thalidomide, glatiramer, leflunomide, vincristine, cytarabine, and combinations thereof.
- 5

**THIS PAGE BLANK (USPTO)**